Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 11 |
List of Tables | 11 | 1 |
List of Figures | 12 | 1 |
Introduction | 13 | 1 |
Global Markets Direct Report Coverage | 13 | 1 |
Escherichia coli Infections Overview | 14 | 1 |
Therapeutics Development | 15 | 2 |
Pipeline Products for Escherichia coli Infections Overview | 15 | 1 |
Pipeline Products for Escherichia coli Infections Comparative Analysis | 16 | 1 |
Escherichia coli Infections Therapeutics under Development by Companies | 17 | 2 |
Escherichia coli Infections Therapeutics under Investigation by Universities/Institutes | 19 | 2 |
Escherichia coli Infections Pipeline Products Glance | 21 | 2 |
Clinical Stage Products | 21 | 1 |
Early Stage Products | 22 | 1 |
Escherichia coli Infections Products under Development by Companies | 23 | 3 |
Escherichia coli Infections Products under Investigation by Universities/Institutes | 26 | 1 |
Escherichia coli Infections Companies Involved in Therapeutics Development | 27 | 29 |
Adenium Biotech ApS | 27 | 1 |
Arsanis, Inc. | 28 | 1 |
AstraZeneca Plc | 29 | 1 |
AvidBiotics Corp | 30 | 1 |
Cellceutix Corp | 31 | 1 |
Debiopharm International SA | 32 | 1 |
Emergent BioSolutions Inc | 33 | 1 |
F. Hoffmann-La Roche Ltd | 34 | 1 |
GangaGen Inc | 35 | 1 |
Hsiri Therapeutics LLC | 36 | 1 |
Johnson &Johnson | 37 | 1 |
Melinta Therapeutics Inc | 38 | 1 |
Merck &Co Inc | 39 | 1 |
Microbiotix Inc | 40 | 1 |
Nabriva Therapeutics AG | 41 | 1 |
Navigen Pharmaceuticals, Inc. | 42 | 1 |
Nosopharm SAS | 43 | 1 |
Novabiotics Ltd | 44 | 1 |
Omnia Molecular Ltd | 45 | 1 |
Paratek Pharmaceuticals Inc | 46 | 1 |
Pherecydes Pharma SA | 47 | 1 |
Phico Therapeutics Ltd | 48 | 1 |
Procarta Biosystems Limited | 49 | 1 |
Sealife PHARMA GMBH | 50 | 1 |
Sequoia Sciences Inc | 51 | 1 |
Soligenix Inc | 52 | 1 |
Syntiron LLC | 53 | 1 |
Tetraphase Pharmaceuticals Inc | 54 | 1 |
Varinel Inc | 55 | 1 |
Escherichia coli Infections Therapeutics Assessment | 56 | 9 |
Assessment by Monotherapy Products | 56 | 1 |
Assessment by Target | 57 | 2 |
Assessment by Mechanism of Action | 59 | 2 |
Assessment by Route of Administration | 61 | 2 |
Assessment by Molecule Type | 63 | 2 |
Drug Profiles | 65 | 93 |
A-3APO Drug Profile | 65 | 1 |
AA-139 Drug Profile | 66 | 1 |
AM-8722 Drug Profile | 67 | 1 |
ASN-4 Drug Profile | 68 | 1 |
AvR2-V10 Drug Profile | 69 | 2 |
BC-7634 Drug Profile | 71 | 1 |
BC-9074 Drug Profile | 72 | 1 |
BC-9529 Drug Profile | 73 | 1 |
BC-9563 Drug Profile | 74 | 1 |
BIZ-20131 Drug Profile | 75 | 1 |
BIZ-20132 Drug Profile | 76 | 1 |
BIZ-20133 Drug Profile | 77 | 1 |
CA-824 Drug Profile | 78 | 1 |
CC-1807 Drug Profile | 79 | 1 |
Debio-1454 Drug Profile | 80 | 1 |
Drugs for Bacterial Infections Drug Profile | 81 | 1 |
dusquetide Drug Profile | 82 | 5 |
Escherichia coli (whole cell) vaccine Drug Profile | 87 | 1 |
Escherichia coli vaccine Drug Profile | 88 | 1 |
Escherichia coli vaccine Drug Profile | 89 | 1 |
ETEC [strain B7A] vaccine Drug Profile | 90 | 1 |
ETEC vaccine Drug Profile | 91 | 1 |
EV-035 Drug Profile | 92 | 2 |
GN-4474 Drug Profile | 94 | 1 |
GNEG SNARE Drug Profile | 95 | 1 |
HT-07 Drug Profile | 96 | 1 |
INX-201 Drug Profile | 97 | 1 |
JNJ-63871860 Drug Profile | 98 | 2 |
MBX-2319 Drug Profile | 100 | 1 |
MDN-0057 Drug Profile | 101 | 2 |
mirandamycin Drug Profile | 103 | 1 |
NBTI-5463 Drug Profile | 104 | 1 |
NOSO-95179 Drug Profile | 105 | 1 |
NP-432 Drug Profile | 106 | 1 |
omadacycline tosylate Drug Profile | 107 | 6 |
Onc-72 Drug Profile | 113 | 1 |
P-100031 Drug Profile | 114 | 1 |
Peptides for Infectious Diseases Drug Profile | 115 | 1 |
PMX-100 Drug Profile | 116 | 1 |
PMX-1091 Drug Profile | 117 | 1 |
PMX-1142 Drug Profile | 118 | 1 |
PMX-1241 Drug Profile | 119 | 1 |
PMX-1278 Drug Profile | 120 | 1 |
PMX-1363 Drug Profile | 121 | 1 |
PMX-1405 Drug Profile | 122 | 1 |
PMX-223 Drug Profile | 123 | 1 |
PMX-229 Drug Profile | 124 | 1 |
PMX-247 Drug Profile | 125 | 1 |
PMX-633 Drug Profile | 126 | 1 |
PMX-668 Drug Profile | 127 | 1 |
PMX-693 Drug Profile | 128 | 1 |
PMX-843 Drug Profile | 129 | 1 |
PP-0121 Drug Profile | 130 | 2 |
Proteins for Infectious Diseases Drug Profile | 132 | 1 |
PT-5 Drug Profile | 133 | 1 |
Recombinant Protein for Escherichia Coli Infections Drug Profile | 134 | 1 |
RX-05 Drug Profile | 135 | 1 |
RXP-873 Drug Profile | 136 | 1 |
SE-1 Drug Profile | 137 | 1 |
Shigetec Drug Profile | 138 | 1 |
SLP-0901 Drug Profile | 139 | 1 |
SLP-0905 Drug Profile | 140 | 1 |
Small Molecule for Malaria and Bacterial Infections Drug Profile | 141 | 1 |
Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease Drug Profile | 142 | 1 |
Small Molecules for Bacterial Infections and Lung Infection Drug Profile | 143 | 1 |
Small Molecules for Escherichia Coli Infections Drug Profile | 144 | 1 |
Small Molecules for Escherichia coli Infections Drug Profile | 145 | 1 |
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections Drug Profile | 146 | 1 |
Small Molecules to Inhibit 16S rRNA, Topoisomerases II and IV for Bacterial Infections Drug Profile | 147 | 1 |
Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections Drug Profile | 148 | 1 |
Small Molecules to Inhibit RecA for Bacterial Infections Drug Profile | 149 | 1 |
SPR-741 Drug Profile | 150 | 1 |
Synthetic Peptide for Gram-Negative Bacterial Infections Drug Profile | 151 | 1 |
Synthetic Peptide for Oncology and Infectious Disease Drug Profile | 152 | 1 |
Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease Drug Profile | 153 | 1 |
Synthetic Peptide to Target Bacterial Cell Membrane for Gram Negative and Gram Positive Bacterial Infections Drug Profile | 154 | 1 |
Synthetic Peptides for Escherichia Coli Infections Drug Profile | 155 | 1 |
TP-6076 Drug Profile | 156 | 1 |
VAR-10100 Drug Profile | 157 | 1 |
Escherichia coli Infections Dormant Projects | 158 | 3 |
Escherichia coli Infections Discontinued Products | 161 | 1 |
Escherichia coli Infections Product Development Milestones | 162 | 2 |
Featured News &Press Releases | 162 | 1 |
Jun 17, 2016: Arsanis Presents Data at ASM Microbe 2016 Demonstrating Protection Against Multidrug-Resistant Escherichia coli using Monoclonal Antibody Technology | 162 | 1 |
Apr 16, 2015: Navigen Receives Phase I SBIR Grant to Support Development of Treatment for Infections Caused by Shiga Toxin-producing E. coli | 162 | 1 |
Sep 01, 2014: AA139, Adenium Clinical Product Candidate Against Multi-Drug Resistant Gram-Negative Bacteria to be Presented at ICAAC in Washington | 163 | 1 |
Appendix | 164 | 2 |
Methodology | 164 | 1 |
Coverage | 164 | 1 |
Secondary Research | 164 | 1 |
Primary Research | 164 | 1 |
Expert Panel Validation | 164 | 1 |
Contact Us | 164 | 1 |
Disclaimer | 165 | 1 |